Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CVTX up on Ranexa SPA

On Thursday, CV Therapeutics (CVTX) popped $2.32 (18%) to $15.53 on 14.8 million shares.

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE